Connor Clark & Lunn Investment Management Ltd. Boosts Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 750.5% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 294,037 shares of the company’s stock after buying an additional 259,463 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Omnicell were worth $12,820,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of OMCL. Nisa Investment Advisors LLC lifted its position in Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares during the period. EntryPoint Capital LLC raised its holdings in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares during the last quarter. CWM LLC boosted its position in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after buying an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. grew its holdings in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on OMCL. JPMorgan Chase & Co. increased their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday. Craig Hallum increased their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Benchmark reiterated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Barclays upped their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company lifted their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and an average target price of $52.00.

Omnicell Price Performance

NASDAQ:OMCL opened at $44.11 on Friday. The firm’s 50-day moving average price is $44.19 and its 200-day moving average price is $37.20. The company has a market capitalization of $2.04 billion, a PE ratio of -109.69, a P/E/G ratio of 35.67 and a beta of 0.81. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.